Review of meningococcal group B vaccines.
Review of meningococcal group B vaccines.
复制标题
DOI:
10.1086/648966
复制
发表时间:
2010-03-01
期刊:
影响因子:
--
通讯作者:
Granoff DM
中科院分区:
文献类型:
--
作者:
Granoff DM
No broadly effective vaccines are available for prevention of group B meningococcal disease, which account for > 50% of all cases. The group B capsule is an autoantigen and is not a suitable vaccine target. Outer-membrane vesicle (OMV) vaccines appear to be safe and effective but serum bactericidal (SBA) responses of infants are specific for a porin protein (PorA), which is antigenically variable. To broaden protection, OMV vaccines have been prepared from more than 1 strain; from mutants with more than 1 PorA; or mutants with genetically detoxified endotoxin and overexpressed desirable antigens such as factor H-binding protein (fHbp). Also, recombinant protein vaccines such as fHbp, given alone or combined with other antigens, are in late-stage clinical development and may be effective against the majority of group B strains. Thus, the prospects have never been better for developing vaccines for prevention of meningococcal disease, including group B strains.
登录
查看更多内容
影响因子:
5.5
作者:
Claassen, I;Meylis, J;Poolman, J
通讯作者:
Poolman, J
影响因子:
15.3
作者:
Comanducci, Maurizio;Bambini, Stefania;Brunelli, Brunella;Adu-Bobie, Jeannette;Arico, Beatrice;Capecchi, Barbara;Giuliani, Marzia Monica;Masignani, Vega;Santini, Laura;Savino, Silvana;Granoff, Dan M;Caugant, Dominique A;Pizza, Mariagrazia;Rappuoli, Rino;Mora, Marirosa
通讯作者:
Mora, Marirosa
影响因子:
6.4
作者:
Beernink, P. T.;Caugant, D. A.;Granoff, D. M.
通讯作者:
Granoff, D. M.
影响因子:
5.5
作者:
Cox, AD;Zou, W;Richards, JC
通讯作者:
Richards, JC
影响因子:
1.7
作者:
Baker, M G;Martin, D R;Lennon, D
通讯作者:
Lennon, D